KR102595837B1 - Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same - Google Patents
Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same Download PDFInfo
- Publication number
- KR102595837B1 KR102595837B1 KR1020200126392A KR20200126392A KR102595837B1 KR 102595837 B1 KR102595837 B1 KR 102595837B1 KR 1020200126392 A KR1020200126392 A KR 1020200126392A KR 20200126392 A KR20200126392 A KR 20200126392A KR 102595837 B1 KR102595837 B1 KR 102595837B1
- Authority
- KR
- South Korea
- Prior art keywords
- spore oil
- deer antler
- reishi mushroom
- reishi
- antler
- Prior art date
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 124
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 124
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 16
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 135
- 210000003056 antler Anatomy 0.000 claims abstract description 110
- 241000282994 Cervidae Species 0.000 claims abstract description 102
- 235000013305 food Nutrition 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 230000037303 wrinkles Effects 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 230000006872 improvement Effects 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- 230000003020 moisturizing effect Effects 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 13
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 8
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 239000003921 oil Substances 0.000 description 110
- 235000019198 oils Nutrition 0.000 description 110
- 210000003491 skin Anatomy 0.000 description 67
- 206010040954 Skin wrinkling Diseases 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- -1 heteroglucan Polymers 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 102000004363 Aquaporin 3 Human genes 0.000 description 10
- 108090000991 Aquaporin 3 Proteins 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 108010050808 Procollagen Proteins 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 101150008656 COL1A1 gene Proteins 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 240000003021 Tsuga heterophylla Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 108010051489 calin Proteins 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Abstract
녹각 영지버섯 포자오일을 포함하는 피부 상태 개선용 화장료 조성물, 식품 조성물, 및 이의 제조 방법에 관한 것이다.It relates to a cosmetic composition for improving skin condition containing deer antler reishi mushroom spore oil, a food composition, and a method for producing the same.
Description
녹각 영지버섯 포자오일 또는 녹각 영지버섯 포자오일 나노리포좀을 포함하는 화장료 조성물, 식품 조성물, 및 이의 제조방법에 관한 것이다.It relates to a cosmetic composition containing deer antler reishi mushroom spore oil or deer antler reishi mushroom spore oil nanoliposomes, a food composition, and a method for producing the same.
버섯은 분류학상 고등균류의 담자균류(일부는 자낭균)에 속한 것으로, 세계적으로 15,000여종이 알려져 있고, 이 중 약 2,000여종이 식용으로 개발 가능하다. 버섯은 균사체 및 그의 영양대사로 얻어지는 대사산물이 축적된 자실체로 구성된다. 일반 식물과 비교하자면, 균사체는 뿌리, 줄기, 잎에 해당되고, 자실체는 꽃에 해당하는데, 균사체는 자실체의 약 4배 이상의 영양소, 약 50 내지 60배 정도의 약용성분을 더 함유하고 있어 버섯의 실체라고 지칭되기도 한다. 최근에는 자실체 및 균 사체의 추출물이나 균사체 배양물이 체질개선이나 각종 병의 예방과 치료에 효과가 있는 것으로 밝혀져 건강식 품이나 의약품으로서의 용도가 크게 증가하고 있는 실정이다. 특히, 버섯이 생산하는 특정 구조의 다당체는 오래 전부터 종래의 화학요법제와는 달리 숙주내 면역기능을 활성 화하여 면역요법제로서의 항암효과를 나타내는 것으로 보고되고 있다. 버섯의 다당체는 세포골격을 구성하는 세포벽 다당, 세포 내에 영양 저장형태로 존재하는 세포 내(intracellular) 다당 및 균체 외로 분비하는 세포 외(extracellular) 다당의 세 가지로 나눌 수 있다. 세포벽과 세포막을 구성하는 다당체는 α-글루칸, β-글루칸, 헤테로글루칸 및 키틴(chitin)질 등이 있다.Mushrooms belong to the taxonomically higher class of Basidiomycota (some of which are Ascomycota), and about 15,000 species are known worldwide, of which about 2,000 species can be developed for food. Mushrooms are composed of mycelium and fruiting bodies in which metabolites obtained from nutrient metabolism are accumulated. Compared to regular plants, the mycelium corresponds to the roots, stems, and leaves, and the fruiting body corresponds to the flower. The mycelium contains about 4 times more nutrients and about 50 to 60 times more medicinal ingredients than the fruiting body, making mushrooms more effective. It is also referred to as an entity. Recently, extracts of fruiting bodies and mycelia or mycelium cultures have been found to be effective in improving constitution and preventing and treating various diseases, and their use as health foods or medicines is increasing significantly. In particular, polysaccharides of a specific structure produced by mushrooms have long been reported to exhibit anti-cancer effects as immunotherapy agents by activating the immune function in the host, unlike conventional chemotherapy agents. Mushroom polysaccharides can be divided into three types: cell wall polysaccharides that make up the cytoskeleton, intracellular polysaccharides that exist in the form of nutrient storage within the cells, and extracellular polysaccharides that are secreted outside the fungal body. Polysaccharides that make up cell walls and membranes include α-glucan, β-glucan, heteroglucan, and chitin.
최근 외부 화학 물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 화장품이 많이 개발되고 있다. 천연물 재료는 피부에 부작용이 적을 뿐만 아니라, 천연 재료를 이용한 화장품에 대한 소비자들의 요구가 높아짐에 따라 화장품 원료로서 개발 가치가 한층 늘어나고 있다. 한국등록특허 제10-0863890호는 차가버섯, 말굽잔나비버섯, 신령버섯 및 노루궁뎅이버섯의 혼합 추출물을 함유 하는 화장료 조성물에 관하여 기재되어 있다. 또한, 한국공개특허 제10-2014-0101875호는 잎새버섯 추출물 및 이를 함유하는 피지 산생을 촉진하기 위한 조성물에 관하여 기재되어 있다. Recently, many cosmetics using natural products have been developed to reduce skin irritation caused by external chemicals. Natural materials not only have fewer side effects on the skin, but their development value as cosmetic raw materials is increasing as consumer demand for cosmetics using natural materials increases. Korean Patent No. 10-0863890 describes a cosmetic composition containing mixed extracts of Chaga mushroom, Horseshoe Mushroom, Holy Mushroom, and Helicoptera Mushroom. Additionally, Korean Patent Publication No. 10-2014-0101875 describes maitake mushroom extract and a composition containing the same for promoting sebum production.
이러한 배경 하에, 본 발명자들은 녹각 영지버섯으로부터 추출된 포자 오일이 우수한 항염 효과, 피부 주름 개선 효과 및 보습 효능을 나타냄을 확인하여 본 발명을 완성하였다.Against this background, the present inventors completed the present invention by confirming that spore oil extracted from deer antler reishi mushroom exhibits excellent anti-inflammatory effects, skin wrinkle improvement effects, and moisturizing effects.
일 양상은 녹각 영지버섯 포자오일을 포함하는 피부 상태 개선용 화장료 조성물을 제공한다.One aspect provides a cosmetic composition for improving skin condition comprising deer antler reishi mushroom spore oil.
다른 양상은 녹각 영지버섯 포자오일을 포함하는 피부 상태 개선용 식품 조성물을 제공한다.Another aspect provides a food composition for improving skin condition comprising deer antler reishi mushroom spore oil.
다른 양상은 녹각 영지버섯 포자오일을 제조하는 방법을 제공한다.Another aspect provides a method of preparing deer antler reishi mushroom spore oil.
다른 양상은 녹각 영지버섯 포자오일 나노리포좀을 제공한다.Another aspect provides deer antler reishi mushroom spore oil nanoliposomes.
다른 양상은 녹각 영지버섯 포자오일 나노리포좀을 제조하는 방법을 제공한다.Another aspect provides a method of preparing deer antler reishi mushroom spore oil nanoliposomes.
다른 양상은 녹각 영지버섯 포자오일 나노리포좀을 포함하는 피부 상태 개선용 화장료 조성물을 제공한다.Another aspect provides a cosmetic composition for improving skin condition comprising deer antler reishi mushroom spore oil nanoliposomes.
다른 양상은 녹각 영지버섯 포자오일 나노리포좀을 포함하는 피부 상태 개선용 식품 조성물을 제공한다.Another aspect provides a food composition for improving skin condition comprising deer antler reishi mushroom spore oil nanoliposomes.
일 양상은 녹각 영지버섯 포자오일을 포함하는 피부 상태 개선용 조성물을 제공한다.One aspect provides a composition for improving skin condition comprising deer antler reishi mushroom spore oil.
본 명세서에서 용어, "피부 상태 개선"은 피부 상태를 개선시키는 것을 총칭하는 의미로 사용될 수 있다. 구체적으로 상기 피부 상태 개선은 항염, 피부 주름 개선, 또는 피부 보습일 수 있으나, 이에 제한되지는 않는다.In this specification, the term “skin condition improvement” may be used to collectively mean improving skin condition. Specifically, the skin condition improvement may be anti-inflammatory, skin wrinkle improvement, or skin moisturizing, but is not limited thereto.
상기 조성물은 항염 효과를 나타낼 수 있다. 상기 항염 효과란 염증을 억제하는 작용을 의미하는 것으로, 상기 염증은 피부염(dermatitis)일 수 있다. 상기 피부염은 습진성 피부염을 말한다. 습진(eczema)이란 급성기에는 가려움을 동반하는 수포(vesicle, 작은 물집), 홍반(erythema, 피부의 적색 변화), 부종 등이 나타나고, 만성기에는 부종과 수포는 감소되는 반면에 태선화(lichniscation, 건조하고 딱딱해진 피부로 인해서 피부에 정상적으로 존재하는 손금 등의 선이 더 뚜렷해지는 것), 인설(scale), 피부색의 변화 등이 형성되는 피부질환이다. 상기 피부염은 예를 들어, 접촉성 피부염(contact dermatitis), 아토피 피부염(atopic dermatitis), 및 지루성 피부염(seborrheic dermatitis)이다. 일 구체예에서, 일 구체예에서, NO assay 및 IL-6 ELISA 분석을 통해, 녹각 영지버섯 포자오일은 현저히 우수한 항염 효과를 나타냄을 확인하였다.The composition may exhibit anti-inflammatory effects. The anti-inflammatory effect refers to the action of suppressing inflammation, and the inflammation may be dermatitis. The dermatitis refers to eczematous dermatitis. In the acute stage, eczema is characterized by itchy vesicles (small blisters), erythema (red changes in the skin), and edema. In the chronic stage, edema and blisters are reduced, while lichenification (lichniscation) causes dryness and swelling. It is a skin disease in which lines that normally exist on the skin (such as palm lines) become more distinct due to hardened skin, scales, and changes in skin color are formed. The dermatitis is, for example, contact dermatitis, atopic dermatitis, and seborrheic dermatitis. In one embodiment, it was confirmed through NO assay and IL-6 ELISA analysis that deer antler reishi mushroom spore oil exhibits a significantly excellent anti-inflammatory effect.
상기 조성물은 피부 주름 개선 효과를 나타낼 수 있다. 상기 "피부 주름 개선"이란 피부의 주름의 수를 감소시키거나 깊이를 감소시키는 작용을 의미할 뿐만 아니라, 주름 개선을 통하여 피부 노화를 억제하는 것도 포함하는 것으로 해석된다. 피부 주름을 개선하기 위하여, 피부 섬유아세포를 활성화시키고 진피내 콜라겐 생성을 촉진하는 물질을 포함할 수 있다. 일 구체예에서, 프로콜라겐 생산 분석 및 Col1a1 mRNA 발현 수준 분석을 통해, 녹각 영지버섯 포자오일은 현저히 우수한 피부 주름 개선 효과를 나타냄을 확인하였다.The composition may exhibit an effect of improving skin wrinkles. The term “skin wrinkle improvement” is interpreted not only to mean the action of reducing the number or depth of skin wrinkles, but also to include suppressing skin aging through wrinkle improvement. To improve skin wrinkles, it may contain substances that activate skin fibroblasts and promote collagen production in the dermis. In one embodiment, through procollagen production analysis and Col1a1 mRNA expression level analysis, it was confirmed that deer antler reishi mushroom spore oil exhibited a significantly excellent skin wrinkle improvement effect.
상기 조성물은 피부 보습 효과를 나타낼 수 있다. 상기 "피부 보습"이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과는 피부의 주름개선, 탄력도 증가에 도움을 줄 수 있다. 일 구체예에서, 아쿠아포린-3(AQP-3) 발현 수준 분석을 통해, 녹각 영지버섯 포자오일은 현저히 우수한 보습 효과를 나타냄을 확인하였다.The composition may exhibit a skin moisturizing effect. The term “skin moisturizing” means increasing moisture in the skin and maintaining a moist state. The skin moisturizing effect can help improve skin wrinkles and increase elasticity. In one embodiment, through analysis of the expression level of aquaporin-3 (AQP-3), it was confirmed that deer antler reishi mushroom spore oil exhibits a significantly excellent moisturizing effect.
본 명세서에서 용어, "녹각 영지버섯(Ganoderma lucidum, Lingzhi mushroom)"은 자실체의 형태가 녹각(사슴뿔)을 닮았으며, 죽은 뒤에도 썩지 않고 광택이 변하지 않는 특성을 지니는 영지버섯의 일종이다. 상기 영지버섯의 종류로서는 녹각 영지버섯 외에도, 적지 영지버섯, 흑지 영지버섯, 자지 영지버섯, 백지 영지버섯, 화지 영지버섯, 청지 영지버섯, 편목 영지버섯, 쓰가 영지버섯 등이 있다. 본 발명자들은 다수의 영지버섯 중에서도 녹각 영지버섯이 항염, 피부 주름 개선 및 보습 등에 있어 현저히 우수한 효과를 나타냄을 확인하여 본 발명을 완성하였다. 상기 녹각 영지버섯은 버섯갓과 버섯대 표면에 옻칠을 한 것과 같은 광택이 있다. 버섯갓 표면은 처음에 누런빛을 띠는 흰색이다가 누런 갈색 또는 붉은 갈색으로 변하고 늙으면 밤갈색으로 변한다. 살은 코르크질이며, 상하 2층으로 상층은 거의 흰색이고 관공(管孔) 부분의 하층은 연한 주황색이다. 갓의 아랫면은 누런 흰색이며 길이 5~10mm의 관공이 1층으로 늘어서 있고 공구는 둥글다. 버섯대는 3~15Х1~2cm이고 붉은 갈색에서 검은 갈색이며 단단한 각피로 싸여 있고 약간 구부러진다. 홀씨는 2중막이며 홀씨 무늬는 연한 갈색이다. 상기 녹각 영지버섯은 불로초(不老草), 만년버섯, 장생녹각, 장생녹각 영지버섯으로 불리기도 한다. In this specification, the term " Ganoderma lucidum (Lingzhi mushroom)" is a type of Ganoderma lucidum whose fruiting body resembles an antler (deer horn) and has the characteristic of not rotting and not changing its luster even after death. The types of reishi mushrooms include, in addition to deer antler reishi mushrooms, red reishi mushrooms, black reishi mushrooms, white reishi mushrooms, white reishi mushrooms, washi reishi mushrooms, blue reishi mushrooms, plank reishi mushrooms, and Tsuga reishi mushrooms. The present inventors completed the present invention by confirming that, among many reishi mushrooms, deer antler reishi mushrooms exhibit significantly superior effects in anti-inflammatory, skin wrinkle improvement, and moisturizing. The deer antler reishi mushroom has a gloss like lacquer on the surface of the mushroom cap and mushroom stem. The surface of the mushroom cap is initially yellowish white, then turns yellowish brown or reddish brown, and then turns chestnut brown as it ages. The flesh is corky and has two layers, upper and lower. The upper layer is almost white and the lower layer near the pores is light orange. The lower surface of the cap is yellowish white, has a single layer of 5-10mm long pores, and the pores are round. The mushroom stalk is 3~15Х1~2cm, red brown to black brown, covered with hard cuticle, and slightly curved. The spore seeds are double-layered and the spore pattern is light brown. The deer antler reishi mushroom is also called the elixir of old age, eternal mushroom, longevity antler, and longevity antler reishi mushroom.
본 명세서에서 용어, "포자오일"은 버섯의 포자를 건조시켜 물리적인 방법으로 파벽(破壁) 후 얻은 오일 형태를 의미하는 것으로, 주로 베타 글루칸 등의 성분을 함유하고, 녹각 영지버섯 포자 유효성분의 집합체이다. As used herein, the term "spore oil" refers to an oil form obtained after drying mushroom spores and crushing them by a physical method. It mainly contains ingredients such as beta-glucan, and contains the active ingredient of deer antler reishi mushroom spores. It is a collection of
상기 포자오일은 녹각 영지버섯으로부터 추출된 것으로, 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있고, 예를 들어, (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매를 이용한 용매추출법 (b) 이산화탄소에 의한 감압 및 고온에 의한 초임계 추출법, (c) 초음파 추출법 또는 (d) 발효 공정을 이용하여 추출할 수 있다. The spore oil is extracted from deer antler reishi mushrooms and can be prepared according to conventional methods known in the art, that is, under conventional conditions of temperature and pressure, using conventional solvents, for example, ( a) Water, anhydrous or hydrous lower alcohols having 1-4 carbon atoms (e.g. methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, Solvent extraction using a solvent selected from the group consisting of butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof (b) supercritical extraction using reduced pressure and high temperature using carbon dioxide, (c) ultrasonic extraction, or (d) fermentation process It can be extracted using .
일 구체예에 있어서, 상기 녹각 영지버섯 포자오일은 초임계 추출법에 의해 제조될 수 있다. 상기 초임계 유체란 "임계온도와 압력 이상에서 있는 유체"로 정의되는 것으로서, 기존의 일반용매 추출법과 차별되는 독특한 특성을 가지고 있다. 초임계 상태에 처해있는 물질은 그 임계점 부근에서 압력을 변화시키면, 밀도, 점도, 확산계수 및 극성 등 많은 물성이 기체에 가까운 상태에서부터 액체에 가까운 상태로까지 연속적으로 매우 큰 변화를 가져온다. 액체의 이산화탄소를 밀폐된 용기에 넣고 가열하면 기-액의 계면이 온도, 압력이 증가하면서 점점 그 경계가 사라지는 것을 볼 수 있다. 초임계 유체는 기체처럼 밀폐된 공간을 가득 채우는 묵직한 유체라고 할 수 있다. 초임계 유체기술은 높은 용해력, 물질이동 및 열이동이 빠르고, 낮은 점도, 높은 확산계수 그리고 낮은 표면장력으로 인한 미세공으로의 빠른 침투성 등과 같은 초임계 유체의 장점을 이용하는 기술이다.In one embodiment, the deer antler reishi mushroom spore oil may be produced by supercritical extraction. The supercritical fluid is defined as “a fluid that exists above critical temperature and pressure,” and has unique characteristics that differentiate it from existing general solvent extraction methods. When the pressure of a substance in a supercritical state is changed near its critical point, many physical properties such as density, viscosity, diffusion coefficient, and polarity continuously change significantly from a state close to a gas to a state close to a liquid. If you put liquid carbon dioxide in a sealed container and heat it, you can see that the gas-liquid interface gradually disappears as the temperature and pressure increase. Supercritical fluid can be said to be a heavy fluid that fills a closed space like a gas. Supercritical fluid technology is a technology that utilizes the advantages of supercritical fluids, such as high dissolving power, fast mass transfer and heat transfer, low viscosity, high diffusion coefficient, and fast penetration into micropores due to low surface tension.
일 구체예에 있어서, 상기 녹각 영지버섯 포자오일은 30 내지 50℃ 및 250 내지 400 기압의 조건에서 초임계 추출법에 의해 제조될 수 있다. 예를 들어, 상기 녹각 영지버섯 포자오일은 녹각영지버섯 포자를 에탄올, 메탄올, 물, 에틸아세테이트, 헥산 및 에틸에테르 중에서 선택되는 1종 또는 2종 이상을 혼합한 혼합유체에 초임계 유체를 공급하고, 30 내지 50℃ 및 250 내지 400 기압의 조건에서 초임계 추출하여 수득할 수 있다.In one embodiment, the deer antler reishi mushroom spore oil may be produced by supercritical extraction under conditions of 30 to 50°C and 250 to 400 atm. For example, the deer antler reishi mushroom spore oil supplies a supercritical fluid to the deer antler reishi mushroom spores in a mixed fluid of one or two or more selected from ethanol, methanol, water, ethyl acetate, hexane, and ethyl ether. , can be obtained by supercritical extraction under conditions of 30 to 50°C and 250 to 400 atmospheres.
상기 추출 방법에서 사용되는 다양한 추출용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를들면, 메탄올, 에탄올, 프로판올및부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 1종 이상의 추출 용매를 사용하여 얻을 수 있다. 한편, 본 발명의 영지버섯(Ganoderma lucidum) 추출물은 상기 언급한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다. 또한, 본 발명의 영지버섯(Ganoderma lucidum) 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 및 발효 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계 추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량컷-오프값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리하거나 자연상태나 각종 미생물을 이용한 발효 산물에 의한 추출물 등, 추가적으로 실시된 다양한 정제 및 추출 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함될 수 있다.Various extraction solvents used in the above extraction method, such as water, anhydrous or hydrous lower alcohols having 1-4 carbon atoms (e.g. methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol , glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof. Meanwhile, it is obvious to those skilled in the art that the Ganoderma lucidum extract of the present invention can be obtained using not only the above-mentioned extraction solvent but also other extraction solvents that exhibit substantially the same effect. In addition, the Ganoderma lucidum extract of the present invention includes not only extracts using the above-described extraction solvent, but also extracts that have undergone conventional purification and fermentation processes. For example, decompression with carbon dioxide, extraction by supercritical extraction at high temperature, extraction by ultrasonic extraction, separation using an ultrafiltration membrane with a certain molecular weight cut-off value, and various chromatography methods (size, charge, hydrophobicity or affinity). Active fractions obtained through various additional purification and extraction methods, such as separation by (designed for separation according to gender) or extracts from fermentation products using natural conditions or various microorganisms, may also be included in the extract of the present invention.
상기 조성물은 조성물 총 중량에 대해 녹각 영지버섯 포자오일을 1%(v/v) 미만, 0.0001%(v/v) 이상 내지 1%(v/v) 미만, 0.001%(v/v) 이상 내지 1%(v/v) 미만, 0.01%(v/v) 이상 내지 1%(v/v) 미만, 0.1%(v/v) 이상 내지 1%(v/v) 미만, 0.0001%(v/v) 내지 0.9%(v/v), 0.0001%(v/v) 내지 0.8%(v/v), 0.0001%(v/v) 내지 0.7%(v/v), 0.0001%(v/v) 내지 0.6%(v/v), 0.0001%(v/v) 내지 0.5%(v/v), 0.001%(v/v) 내지 0.5%(v/v), 0.01%(v/v) 내지 0.5%(v/v), 또는 0.1%(v/v) 내지 0.5%(v/v)로 포함할 수 있다. 조성물 총 중량에 대해 녹각 영지버섯 포자오일의 함량이 1%(v/v) 이상일 경우 세포 독성 문제가 발생할 수 있다.The composition contains less than 1% (v/v), more than 0.0001% (v/v) to less than 1% (v/v), more than 0.001% (v/v) of deer antler reishi mushroom spore oil relative to the total weight of the composition. Less than 1% (v/v), 0.01% (v/v) or more to less than 1% (v/v), 0.1% (v/v) or more to less than 1% (v/v), 0.0001% (v/ v) to 0.9% (v/v), 0.0001% (v/v) to 0.8% (v/v), 0.0001% (v/v) to 0.7% (v/v), 0.0001% (v/v) to 0.6% (v/v), 0.0001% (v/v) to 0.5% (v/v), 0.001% (v/v) to 0.5% (v/v), 0.01% (v/v) to 0.5 % (v/v), or 0.1% (v/v) to 0.5% (v/v). If the content of deer antler reishi mushroom spore oil is more than 1% (v/v) relative to the total weight of the composition, cytotoxicity problems may occur.
용어, "유효성분으로 포함"은 상기에서 언급한 효과를 나타낼 수 있는 정도로 본 명세서의 녹각 영지버섯 포자오일이 첨가되는 것을 의미하고, 약물전달 및 안정화 등을 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 포뮬레이션(formulation)되는 것을 포함하는 의미이다.The term "included as an active ingredient" means that the deer antler reishi mushroom spore oil of the present specification is added to the extent that it can exhibit the effects mentioned above, and various ingredients are added as sub-ingredients for drug delivery and stabilization, etc. to form various forms. This means that it includes being formulated.
상기 조성물은 화장료 조성물일 수 있다.The composition may be a cosmetic composition.
상기 화장료 조성물은 필요에 따라 계면활성제, 산화방지제, 방부제, pH 조절제, 보습제, 윤활제 등의 성분을 더 첨가할 수 있다. 또한, 상기 화장료 조성물은 피부에 필수 영양소를 보조적으로 제공할 수 있는 물질을 추가로 포함할 수 있다. 상기 화장료 조성물은 천연향, 화장품향, 또는 식물 추출물이 포함되지만 이들에 국한되지 않는 보조제를 함유할 수 있다. The cosmetic composition may further add ingredients such as surfactants, antioxidants, preservatives, pH adjusters, moisturizers, and lubricants as needed. In addition, the cosmetic composition may additionally contain substances that can supplementally provide essential nutrients to the skin. The cosmetic composition may contain adjuvants including, but not limited to, natural fragrances, cosmetic fragrances, or plant extracts.
상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들면, 용액, 유탁액, 현탁액, 페이스트, 크림, 로션, 겔, 파우더, 스프레이, 계면활성제-함유 클린징, 오일, 비누, 액체 세정료, 입욕제, 파운데이션, 메이크업베이스, 에센스, 화장수, 폼, 팩, 유연수, 선 스크린 크림, 선오일 등의 제형으로 제조될 수 있고, 바람직하게는 피부외용연고, 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 에멀젼 또는 오일젤의 제형으로 제조될 수 있는데, 이때, 사용되는 담체는 화장품의 제형에 따라 선택적으로 사용될 수 있다. 예를 들어, 연고, 페이스트, 크림 또는 젤 형태의 화장품을 제조할 경우에는, 담체 성분으로서 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등을 단독으로 또는 조합하여 사용할 수 있고; 파우더 또는 스프레이 형태의 화장품을 제조할 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더, 클로로플루오로하이드로카본, 프로판/부탄, 디메틸 에테르 등을 단독으로 또는 조합하여 사용할 수 있으며; 용액 또는 유탁액 형태의 화장품을 제조할 경우에는, 담체 성분으로서 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일, 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르 등을 단독으로 또는 조합하여 사용할 수 있고; 현탁액 형태의 화장품을 제조할 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르, 폴리옥시에틸렌 소르비탄 에스테르, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가, 트라칸트 등을 단독으로 또는 조합하여 사용할 수 있으며; 화장비누 형태의 화장품을 제조할 경우에는, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등을 단독으로 또는 조합하여 사용할 수 있다.The cosmetic composition can be prepared in any formulation commonly prepared in the art, for example, solution, emulsion, suspension, paste, cream, lotion, gel, powder, spray, surfactant-containing cleansing, oil. , soap, liquid detergent, bath additive, foundation, makeup base, essence, lotion, foam, pack, softening water, sunscreen cream, sun oil, etc., preferably ointment for external use, softening lotion, and nutrition. It can be manufactured in the form of lotion, nutritional cream, massage cream, essence, pack, emulsion or oil gel. At this time, the carrier used can be selectively used depending on the formulation of the cosmetic. For example, when manufacturing cosmetics in the form of ointments, pastes, creams or gels, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. are used as carrier ingredients. Can be used alone or in combination; When manufacturing cosmetics in the form of powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, chlorofluorohydrocarbon, propane/butane, dimethyl ether, etc. are used alone as carrier ingredients. Or it can be used in combination; When manufacturing cosmetics in the form of a solution or emulsion, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, cottonseed oil, and peanut are used as carrier ingredients. oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol fatty ester, polyethylene glycol, or sorbitan fatty acid ester, etc. can be used alone or in combination; When preparing cosmetics in the form of a suspension, water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, microcrystalline cellulose, and aluminum metahydroxide are used as carrier ingredients. , bentonite, agar, tracant, etc. can be used alone or in combination; When manufacturing cosmetics in the form of toilet soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. are used as carrier ingredients. It can be used alone or in combination.
또한, 상기 조성물은 피부외용제용 조성물일 수 있다.Additionally, the composition may be a composition for external skin application.
본 명세서에서, 상기 피부외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션, 또는 그 조합일 수 있다. 상기 피부외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다. 상기 피부외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 칼린의 과실의 열수추출물, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류등도 적절하게 배합할 수 있다.In this specification, the external skin agent may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The skin external preparations include ingredients commonly used in external skin preparations such as cosmetics and medicines, such as aqueous ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or a combination thereof may be appropriately mixed according to need. The skin external preparations include metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belafamil, licorice extract, glablidin, and calin. Hot water extract of fruit, various herbal medicines, drugs such as tocopherol acetate, glytylitinic acid, tranexamic acid and its derivatives or salts, vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, kojic acid, glucose, fructose, Sugars such as trehalose can also be appropriately mixed.
상기 조성물은 약학적 조성물일 수 있다.The composition may be a pharmaceutical composition.
상기 약학적 조성물은 약제학적으로 허용가능한 희석제 또는 담체를 추가적으로 포함할 수 있다. 상기 희석제는 유당, 옥수수 전분, 대두유, 미정질 셀룰로오스, 또는 만니톨, 활택제로는 스테아린산 마그네슘, 탈크, 또는 그 조합일 수 있다. 상기 담체는 부형제, 붕해제, 결합제, 활택제, 또는 그 조합일 수 있다. 상기 부형제는 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오즈, 또는 그 조합일 수 있다. 상기 붕해제는 카르복시메틸셀룰로오스 칼슘, 전분글리콜산 나트륨, 무수인산일수소 칼슘, 또는 그 조합일 수 있다. 상기 결합제는 폴리비닐피롤리돈, 저치환도 히드록시프로필셀룰로오즈, 히드록시프로필셀룰로오즈, 또는 그 조합일 수 있다. 상기 활택제는 스테아린산 마그네슘, 이산화규소, 탈크, 또는 그 조합일 수 있다.The pharmaceutical composition may additionally include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, disintegrant, binder, lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium monohydrogen phosphate anhydride, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
상기 약학적 조성물은 경구 또는 비경구 투여 제형으로 제형화될 수 있다. 경구 투여 제형은 과립제, 산제, 액제, 정제, 캅셀제, 건조시럽제, 또는 그 조합일 수 있다. 비경구 투여 제형은 주사제일 수 있다.The pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrup, or combinations thereof. Parenteral dosage forms may be injectable.
상기 조성물은 식품 조성물, 건강보조식품, 기능성식품, 또는 식품첨가제 조성물일 수 있다.The composition may be a food composition, health supplement, functional food, or food additive composition.
본 발명에서 용어, "기능성식품"이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 가공한 식품을 의미한다. 본 발명의 조성물을 피부 개선 등을 목적으로 기능성식품에 포함시킬 경우, 상기 조성물을 그대로 포함하여 사용하거나 다른 기능성식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있다.In the present invention, the term "functional food" refers to a group of foods or processed foods to which added value has been added to the food to function and express the function of the food for a specific purpose using physical, biochemical, biotechnological methods, etc. When the composition of the present invention is included in functional food for the purpose of improving skin, etc., the composition can be used as is or together with other functional food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
상기 기능성식품의 제형은 특별히 이에 제한되지 않으나, 예를 들어 액제, 과립제, 분말제, 캡슐제, 정제, 환제, 현탁제 또는 젤제의 형태로 제조되어 사용될 수 있다.The formulation of the functional food is not particularly limited, but may be prepared and used in the form of, for example, liquid, granule, powder, capsule, tablet, pill, suspension, or gel.
유효 성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 명세서의 조성물은 원료에 대하여 15 중량부 이하의 양으로 첨가될 수 있다. 상기 건강기능식품의 종류에는 특별한 제한은 없다. 건강기능식품의 종류 중 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 건강식품 조성물은 또한 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제, 또는 그 조합을 함유할 수 있다. 상기 건강기능식품 조성물은 또한, 천연 과일쥬스, 과일쥬스 음료, 야채 음료의 제조를 위한 과육, 또는 그 조합을 함유할 수 있다.The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). In general, when manufacturing food or beverages, the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw materials. There are no particular restrictions on the types of health functional foods. Among the types of health functional foods, beverage compositions may contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary beverages. The natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used. The health food composition also contains nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonated beverages. It may contain the carbonating agent used, or a combination thereof. The health functional food composition may also contain pulp for the production of natural fruit juice, fruit juice beverage, vegetable beverage, or a combination thereof.
다른 양상은 상기 녹각 영지버섯 포자오일을 제조하는 방법을 제공한다.Another aspect provides a method of preparing the deer antler reishi mushroom spore oil.
상기 방법은 녹각 영지버섯 포자를 초임계 추출하는 단계를 포함한다.The method includes supercritical extraction of deer antler reishi mushroom spores.
상기 초임계 추출은 30 내지 50℃ 및 250 내지 400기압의 조건에서 수행될 수 있다. 상기 초임계 추출은 10분 내지 120분 동안 수행될 수 있다.The supercritical extraction may be performed under conditions of 30 to 50°C and 250 to 400 atmospheres. The supercritical extraction may be performed for 10 to 120 minutes.
일 구체예에 있어서, 상기 방법은 녹각 영지버섯 포자를 에탄올, 메탄올, 물, 에틸아세테이트, 헥산 및 에틸에테르 중에서 선택되는 1종 또는 2종 이상을 혼합하여 혼합유체를 제조하는 단계; 및In one embodiment, the method includes preparing a mixed fluid by mixing deer antler reishi mushroom spores with one or two or more selected from ethanol, methanol, water, ethyl acetate, hexane, and ethyl ether; and
상기 혼합유체에 초임계 유체를 공급하여 30 내지 50℃ 및 250 내지 400기압의 조건에서 초임계 추출하는 단계를 포함하는 단계를 포함할 수 있다.It may include supplying a supercritical fluid to the mixed fluid and performing supercritical extraction under conditions of 30 to 50°C and 250 to 400 atmospheres.
다른 양상은 녹각 영지버섯 포자오일 나노리포좀을 제공한다.Another aspect provides deer antler reishi mushroom spore oil nanoliposomes.
상기 녹각 영지버섯 포자오일 나노리포좀은 녹각 영지버섯 포자오일, 레시틴, 잔탄검 및 정제수를 포함할 수 있다.The deer antler reishi mushroom spore oil nanoliposome may contain deer antler reishi mushroom spore oil, lecithin, xanthan gum, and purified water.
상기 녹각 영지버섯 포자오일은 일 양상에 따른 녹각 영지버섯 포자오일일 수 있다. 상기 녹각 영지버섯 포자오일은 30 내지 50℃ 및 250 내지 400 기압의 조건에서 초임계 추출법에 의해 제조된 것일 수 있다.The deer antler reishi mushroom spore oil may be antler reishi mushroom spore oil according to one aspect. The deer antler reishi mushroom spore oil may be prepared by a supercritical extraction method under conditions of 30 to 50°C and 250 to 400 atmospheres.
상기 녹각 영지버섯 포자오일은 나노리포좀 총 중량에 대해 3.0 내지 7.0 중량%, 3.0 내지 6.5 중량%, 3.0 내지 6.0 중량%, 3.0 내지 5.5 중량%, 4.0 내지 7.0 중량%, 4.0 내지 6.5 중량%, 4.0 내지 6.0 중량%, 4.0 내지 5.5 중량%, 4.5 내지 7.0 중량%, 4.5 내지 6.5 중량%, 4.5 내지 6.0 중량%, 또는 4.5 내지 5.5 중량%로 포함될 수 있다.The deer antler reishi mushroom spore oil is 3.0 to 7.0% by weight, 3.0 to 6.5% by weight, 3.0 to 6.0% by weight, 3.0 to 5.5% by weight, 4.0 to 7.0% by weight, 4.0 to 6.5% by weight, 4.0% by weight, based on the total weight of nanoliposomes. It may be included in an amount of from 6.0% by weight, 4.0 to 5.5% by weight, 4.5 to 7.0% by weight, 4.5 to 6.5% by weight, 4.5 to 6.0% by weight, or 4.5 to 5.5% by weight.
상기 레시틴은 대두 레시틴일 수 있다. 상기 레시틴은 수첨 대두 레시틴일 수 있다.The lecithin may be soy lecithin. The lecithin may be hydrogenated soy lecithin.
상기 레시틴은 나노리포좀 총 중량에 대해 2.0 내지 6.0 중량%, 2.0 내지 5.0 중량%, 2.0 내지 4.5 중량%, 3.0 내지 6.0 중량%, 3.0 내지 5.0 중량%, 3.0 내지 4.5 중량%, 3.5 내지 6.0 중량%, 3.5 내지 5.0 중량%, 3.5 내지 4.5 중량%, 또는 3.6 내지 4.4 중량%로 포함될 수 있다.The lecithin is 2.0 to 6.0% by weight, 2.0 to 5.0% by weight, 2.0 to 4.5% by weight, 3.0 to 6.0% by weight, 3.0 to 5.0% by weight, 3.0 to 4.5% by weight, 3.5 to 6.0% by weight, based on the total weight of nanoliposomes. , 3.5 to 5.0% by weight, 3.5 to 4.5% by weight, or 3.6 to 4.4% by weight.
상기 잔탄검은 나노리포좀 총 중량에 대해 0.1 내지 1.0 중량%, 0.1 내지 0.9 중량%, 0.1 내지 0.8 중량%, 0.2 내지 1.0 중량%, 0.2 내지 0.9 중량%, 0.2 내지 0.8 중량%, 0.3 내지 1.0 중량%, 0.3 내지 0.9 중량%, 0.3 내지 0.8 중량%, 0.4 내지 1.0 중량%, 0.4 내지 0.9 중량%, 0.4 내지 0.8 중량%, 0.5 내지 1.0 중량%, 0.5 내지 0.9 중량%, 0.5 내지 0.8 중량%, 또는 0.585 내지 0.715 중량%로 포함될 수 있다.The xanthan gum is 0.1 to 1.0% by weight, 0.1 to 0.9% by weight, 0.1 to 0.8% by weight, 0.2 to 1.0% by weight, 0.2 to 0.9% by weight, 0.2 to 0.8% by weight, 0.3 to 1.0% by weight based on the total weight of nanoliposomes. , 0.3 to 0.9% by weight, 0.3 to 0.8% by weight, 0.4 to 1.0% by weight, 0.4 to 0.9% by weight, 0.4 to 0.8% by weight, 0.5 to 1.0% by weight, 0.5 to 0.9% by weight, 0.5 to 0.8% by weight, or It may be included in 0.585 to 0.715% by weight.
상기 나노리포좀은 녹각 영지버섯 포자오일 4.0 내지 6.0 중량%, 수첨 대두 레시틴 3.0 내지 5.0 중량%, 잔탄검 0.1 내지 1.0 중량% 및 잔량의 정제수를 포함할 수 있다.The nanoliposome may contain 4.0 to 6.0% by weight of deer antler reishi mushroom spore oil, 3.0 to 5.0% by weight of hydrogenated soy lecithin, 0.1 to 1.0% by weight of xanthan gum, and the remaining amount of purified water.
상기 나노리포좀은 녹각 영지버섯 포자오일 4.0 내지 6.0 중량%, 수첨 대두 레시틴 3.0 내지 5.0 중량%, 잔탄검 0.1 내지 1.0 중량% 및 잔량의 정제수로 필수적으로 구성될 수 있다.The nanoliposome may be composed essentially of 4.0 to 6.0% by weight of deer antler reishi mushroom spore oil, 3.0 to 5.0% by weight of hydrogenated soy lecithin, 0.1 to 1.0% by weight of xanthan gum, and the remaining amount of purified water.
상기 나노리포좀은 나노리포좀의 구조 또는 특성에 영향을 미치지 않는 당업계의 통상적인 성분을 포함할 수 있다. 예를 들어, 상기 나노리포좀은 통상적인 pH 조절제, 방부제, 향료, 산화방지제 등을 더 포함할 수 있다.The nanoliposome may contain ingredients common in the art that do not affect the structure or properties of the nanoliposome. For example, the nanoliposome may further include conventional pH adjusters, preservatives, fragrances, antioxidants, etc.
상기 나노리포좀은 100 nm 이하, 100 nm 미만, 50 내지 100 nm, 60 내지 100 nm, 70 내지 100 nm, 80 내지 100nm, 90 내지 100 nm, 95 내지 100 nm, 95 내지 99 nm, 96 내지 100 nm, 96 내지 99 nm, 97 내지 100 nm, 97 내지 99 nm, 또는 약 98 nm의 직경을 갖는 것일 수 있다. 상기 녹각 영지버섯 포자오일 나노리포좀은 크기가 100 nm 이하로 매우 작기 때문에, 피부 및 세포 침투력이 뛰어나 모든 효능적인 측면이 극대화될 수 있다. 따라서, 상기 녹각 영지버섯 포자오일 나노리포좀은 피부 및 세포 침투력이 뛰어나 피부 상태 개선 효과가 매우 우수할 수 있다. 일 실시예에서, 상기 녹각 영지버섯 포자오일 나노리포좀은 -10℃에서 5개월간 보관 후에도 크기 변화가 거의 없었으므로, 제형 안정성이 우수함을 확인하였다.The nanoliposomes are 100 nm or less, less than 100 nm, 50 to 100 nm, 60 to 100 nm, 70 to 100 nm, 80 to 100 nm, 90 to 100 nm, 95 to 100 nm, 95 to 99 nm, 96 to 100 nm. , may have a diameter of 96 to 99 nm, 97 to 100 nm, 97 to 99 nm, or about 98 nm. Since the deer antler reishi mushroom spore oil nanoliposomes are very small (less than 100 nm in size), they have excellent skin and cell penetration and can maximize all efficacy aspects. Therefore, the deer antler reishi mushroom spore oil nanoliposome has excellent skin and cell penetration and can be very effective in improving skin condition. In one example, the deer antler reishi mushroom spore oil nanoliposome showed little change in size even after storage at -10°C for 5 months, confirming excellent formulation stability.
다른 양상은 상기 녹각 영지버섯 포자오일 나노리포좀을 제조하는 방법을 제공한다.Another aspect provides a method of preparing the deer antler reishi mushroom spore oil nanoliposomes.
상기 방법은 (1) 녹각 영지버섯 포자오일 및 수첨 대두 레시틴을 교반하는 단계; The method includes (1) stirring deer antler reishi mushroom spore oil and hydrogenated soy lecithin;
(2) 정제수 및 잔탄검을 교반하여 얻은 혼합물을 단계 (1)의 혼합물에 첨가하여 균일화하는 단계; 및(2) adding the mixture obtained by stirring purified water and xanthan gum to the mixture of step (1) to homogenize it; and
(3) 상기 균일화물을 균질화기를 이용하여 균질화하여 나노리포좀을 수득하는 단계를 포함할 수 있다.(3) It may include the step of homogenizing the homogenized product using a homogenizer to obtain nanoliposomes.
상기 단계 (1)에서, 교반은 70 내지 90℃에서 수행될 수 있다.In step (1), stirring may be performed at 70 to 90°C.
상기 단계 (2)에서, 교반은 60 내지 80℃에서 수행될 수 있다.In step (2), stirring may be performed at 60 to 80°C.
상기 단계 (2)에서, 균일화는 60 내지 80℃에서 수행될 수 있다.In step (2), homogenization may be performed at 60 to 80°C.
상기 단계 (2) 이후에 추가적으로 교반하여 균일화하는 단계를 더 포함할 수 있다.After step (2), a step of additional stirring and homogenization may be further included.
상기 단계 (3)에서 균질화는 800 내지 1,200 bar, 800 내지 1,100 bar, 900 내지 1,200 bar, 900 내지 1,100 bar, 또는 약 1,000 bar에서 수행될 수 있다.Homogenization in step (3) may be performed at 800 to 1,200 bar, 800 to 1,100 bar, 900 to 1,200 bar, 900 to 1,100 bar, or about 1,000 bar.
다른 양상은 상기 녹각 영지버섯 포자오일 나노리포좀을 포함하는 피부 상태 개선용 조성물을 제공한다.Another aspect provides a composition for improving skin condition including the deer antler reishi mushroom spore oil nanoliposome.
상기 녹각 영지버섯 포자오일 나노리포좀, 및 피부 상태 개선에 관한 상세는 상술한 바와 같다.Details regarding the deer antler reishi mushroom spore oil nanoliposome and improvement of skin condition are as described above.
상기 녹각 영지버섯 포자오일 나노리포좀은 조성물 총 중량에 대해 유효성분인 녹각 영지버섯 포자오일을 0.0001%(v/v) 이상 내지 1%(v/v) 미만으로 포함할 수 있다. 녹각 영지버섯 포자오일의 함량이 1%(v/v) 이상일 경우 세포 독성 문제가 발생할 수 있다.The deer antler reishi mushroom spore oil nanoliposome may contain 0.0001% (v/v) or more to less than 1% (v/v) of deer antler reishi mushroom spore oil, which is an active ingredient, based on the total weight of the composition. If the content of deer antler reishi mushroom spore oil exceeds 1% (v/v), cytotoxicity problems may occur.
상기 조성물은 화장료 조성물, 피부 외용제용 조성물, 약학적 조성물, 또는 식품 조성물일 수 있다.The composition may be a cosmetic composition, a composition for external application to the skin, a pharmaceutical composition, or a food composition.
상기 화장료 조성물, 피부외용제용 조성물, 약학적 조성물, 및 식품 조성물에 관한 상세는 상술한 바와 같다.Details regarding the cosmetic composition, composition for external skin application, pharmaceutical composition, and food composition are as described above.
다른 양상은 유효한 양의 상기한 조성물을 그를 필요로 하는 개체에 투여하는 단계를 포함하는 개체의 피부 상태를 개선하는 방법을 제공한다.Another aspect provides a method of improving the condition of the skin of a subject comprising administering to a subject in need thereof an effective amount of the composition described above.
상기 개체의 피부 상태는 염증, 피부 주름, 또는 피부 건조와 관련된 상태일 수 있다. The subject's skin condition may be a condition associated with inflammation, skin wrinkling, or skin dryness.
용어, "투여하는", "도입하는", 및 "이식하는"은 상호교환적으로 사용되고 일 구체예에 따른 조성물의 원하는 부위로의 적어도 부분적 국소화를 초래하는 방법 또는 경로에 의한 개체 내로의 일 구체예에 따른 조성물의 배치를 의미할 수 있다. The terms “administering,” “introducing,” and “implanting” are used interchangeably and refer to a method or route that results in at least partial localization of the composition according to one embodiment to the desired site. It may refer to the arrangement of the composition according to the example.
투여는 당업계에 알려진 방법에 의하여 투여될 수 있다. 투여는 예를 들면, 정맥내, 근육내, 경구, 경피 (transdermal), 점막, 코안 (intranasal), 기관내 (intratracheal) 또는 피하 투여와 같은 경로로, 임의의 수단에 의하여 개체로 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여될 수 있다. 상기 투여는 피부에 도포하는 것일 수 있다.Administration can be done by methods known in the art. Administration may be administered directly to the subject by any means, such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. You can. The administration may be administered systemically or locally. The administration may be application to the skin.
상기 개체는 포유동물, 예를 들면, 사람, 소, 말, 돼지, 개, 양, 염소, 또는 고양이일 수 있다. 상기 개체는 피부 상태 개선, 예를 들어 피부 보습, 피부 염증 억제, 피부 주름 개선 효과를 필요로 하는 개체일 수 있다.The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an individual in need of skin condition improvement, for example, skin moisturizing, skin inflammation inhibition, and skin wrinkle improvement effects.
일 양상에 따른 녹각 영지버섯으로부터 추출된 포자오일을 포함하는 화장료 조성물 또는 식품 조성물은 항염, 피부 주름 개선, 또는 피부 보습력에 있어서 현저히 개선된 효과를 나타낼 수 있다.A cosmetic composition or food composition containing spore oil extracted from deer antler reishi mushroom according to one aspect may exhibit significantly improved effects in anti-inflammatory, skin wrinkle improvement, or skin moisturizing ability.
다른 양상에 따른 녹각 영지버섯 포자오일 나노리포좀은 크기가 작고 제형이 안정하므로 피부 침투력이 탁월하여 우수한 항염, 피부 주름 개선, 또는 피부 보습 효과를 나타낼 수 있다.Antler reishi mushroom spore oil nanoliposomes according to different aspects have a small size and stable formulation, so they have excellent skin penetration and can exhibit excellent anti-inflammatory, skin wrinkle improvement, or skin moisturizing effects.
도 1은 녹각 영지버섯으로부터 추출된 포자오일의 항염 효과를 확인한 NO Assay 결과를 나타낸 도면이다.
도 2는 녹각 영지버섯으로부터 추출된 포자오일의 항염 효과를 확인한 전염증성 사이토카인인 IL-6의 ELISA 결과를 나타낸 도면이다.
도 3은 녹각 영지버섯으로부터 추출된 포자오일의 피부 주름 개선 효과를 확인한 프로콜라겐의 생산량을 나타낸 도면이다.
도 4는 녹각 영지버섯으로부터 추출된 포자오일의 피부 주름 개선 효과를 확인한 콜라겐 생성 관련 유전자인 Col1a1의 mRNA 발현 수준을 나타낸 도면이다.
도 5는 녹각 영지버섯으로부터 추출된 포자오일의 보습 효과를 확인한 아쿠아포린-3(AQP-3)의 mRNA 발현 수준을 나타낸 도면이다.
도 6은 녹각 영지버섯 포자오일의 세포 독성 시험 결과를 나타낸 도면이다.
도 7은 녹각 영지버섯 포자오일 나노리포좀의 크기 분포를 나타낸 그래프이다. 빨간색 라인: 초기 측정 결과; 녹색 라인: -10℃에서 5개월간 보관 후 측정 결과.Figure 1 is a diagram showing the results of the NO Assay confirming the anti-inflammatory effect of spore oil extracted from deer antler reishi mushroom.
Figure 2 is a diagram showing the ELISA results of IL-6, a pro-inflammatory cytokine, confirming the anti-inflammatory effect of spore oil extracted from deer antler reishi mushroom.
Figure 3 is a diagram showing the production volume of procollagen confirming the skin wrinkle improvement effect of spore oil extracted from deer antler reishi mushroom.
Figure 4 is a diagram showing the mRNA expression level of Col1a1, a gene related to collagen production, confirming the skin wrinkle improvement effect of spore oil extracted from deer antler reishi mushroom.
Figure 5 is a diagram showing the mRNA expression level of aquaporin-3 (AQP-3), confirming the moisturizing effect of spore oil extracted from deer antler reishi mushroom.
Figure 6 is a diagram showing the results of a cytotoxicity test of deer antler reishi mushroom spore oil.
Figure 7 is a graph showing the size distribution of deer antler reishi mushroom spore oil nanoliposomes. Red line: initial measurement result; Green line: Measurement results after storage at -10℃ for 5 months.
이하 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.This will be described in more detail through examples below. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
실시예 1. 녹각 영지버섯 포자오일의 제조Example 1. Preparation of deer antler reishi mushroom spore oil
녹각 영지버섯으로부터 포자 오일을 추출하였다. 구체적으로, 녹각영지버섯 포자를 건조한 후 에탄올, 메탄올, 물, 에틸아세테이트, 헥산 및 에틸에테르 중에서 선택되는 1종 또는 2종 이상을 혼합한 혼합유체를 교반하였다. 이후, 상기 혼합물을 초임계 추출조에 넣고 초임계 유체를 공급하였다. 추출조의 압력을 330기압으로 유지시키며 추출조 내부의 온도를 0.5℃/분 속도로 42℃까지 승온시켰다. 추출조의 온도와 압력을 30 내지 50℃, 250 내지 400기압으로 50분간 유지한 후, 상압으로 감압하여 첫 번째 혼합 추출물을 수득하여, 녹각 영지버섯 포자오일을 제조하였다.Spore oil was extracted from deer antler reishi mushroom. Specifically, after drying the deer antler reishi mushroom spores, a mixed fluid containing one or two or more selected from ethanol, methanol, water, ethyl acetate, hexane, and ethyl ether was stirred. Thereafter, the mixture was placed in a supercritical extraction tank and supercritical fluid was supplied. The pressure of the extraction tank was maintained at 330 atmospheres, and the temperature inside the extraction tank was raised to 42°C at a rate of 0.5°C/min. The temperature and pressure of the extraction tank were maintained at 30 to 50°C and 250 to 400 atm for 50 minutes, and then the pressure was reduced to normal pressure to obtain the first mixed extract to prepare deer antler reishi mushroom spore oil.
실시예 2. 녹각 영지버섯 포자오일 나노리포좀의 제조Example 2. Preparation of deer antler reishi mushroom spore oil nanoliposomes
하기 표 1에 기재된 성분 및 함량(중량%)으로 녹각 영지버섯 포자오일 나노리포좀을 제조하였다.Antler reishi mushroom spore oil nanoliposomes were prepared using the ingredients and contents (% by weight) listed in Table 1 below.
구체적으로, 메인 용해조에 정제수와 잔탄검을 첨가한 후, 80℃에서 가온 교반하여 완전히 용해시켰다. 별도의 용해조에 실시예 1에서 제조된 녹각 영지버섯 포자오일과 수첨 대두 레시틴을 첨가하여 70℃에서 가온 교반하여 용해시켰다. 상기 별도의 용해조에서 용해시킨 용해물을 메인 용해조에 첨가한 후, 70℃에서 5분간 교반하여 균일화하였다. 증류수를 첨가하고 5분간 추가적으로 교반하여 1차 균일화물을 제조하였다. 제조된 1차 균일화물을 고압균질화기(High pressure homogenizer)를 이용하여 1,000 bar에서 2회 처리한 후 안정화된 나노리포좀을 수득하였다.Specifically, purified water and xanthan gum were added to the main dissolution tank, then heated and stirred at 80°C to completely dissolve them. In a separate dissolution tank, the deer antler reishi mushroom spore oil and hydrogenated soy lecithin prepared in Example 1 were added and dissolved by heating and stirring at 70°C. The lysate dissolved in the separate dissolution tank was added to the main dissolution tank and stirred at 70°C for 5 minutes to homogenize. Distilled water was added and stirred for additional 5 minutes to prepare the first homogenate. The prepared first homogenizer was treated twice at 1,000 bar using a high pressure homogenizer, and then stabilized nanoliposomes were obtained.
* q.s.: 적량 * qs: Appropriate amount
실험예 1. 녹각 영지버섯 포자오일의 항염 효과 확인Experimental Example 1. Confirmation of anti-inflammatory effect of deer antler reishi mushroom spore oil
녹각 영지버섯 포자오일의 항염 효과를 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 NO Assay (Nitric oxide Reduction Assay)을 수행하였다. 구체적으로, LPS(liposaccharides) 처리 후 녹각 영지버섯 포자오일을 0.5%(v/v), 0.25%(v/v) 또는 0.1%(v/v) 농도로 처리한 경우의 산화질소 생성 억제 효과를 확인하였다. 포자오일을 처리하지 않은 군(MO: media only)을 음성 대조군으로, LPS만을 처리한 군을 양성 대조군으로 하였다. To confirm the anti-inflammatory effect of deer antler reishi mushroom spore oil, NO Assay (Nitric oxide Reduction Assay) was performed at various concentrations of the spore oil prepared in Example 1. Specifically, the effect of suppressing nitric oxide production when treated with antler reishi mushroom spore oil at a concentration of 0.5% (v/v), 0.25% (v/v), or 0.1% (v/v) after LPS (liposaccharides) treatment was investigated. Confirmed. The group not treated with spore oil (MO: media only) was used as a negative control, and the group treated only with LPS was used as a positive control.
그 결과, 도 1에 나타낸 바와 같이, 녹각 영지버섯 포자오일을 처리한 경우, LPS 처리에 의해 유도된 산화질소의 생성을 유의적으로 억제함을 확인하였다. As a result, as shown in Figure 1, it was confirmed that treatment with deer antler reishi mushroom spore oil significantly inhibited the production of nitric oxide induced by LPS treatment.
또한, 녹각 영지버섯 포자오일의 항염 효과를 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 처리에 따른 전염증성 사이토카인 (Pro-inflammatory cytokine)인 IL-6의 수준을 확인한 ELISA(enzyme-linked immunosorbent assay)를 수행하였다. IL-6은 대식세포에서 분비되는 활성인자로 면역반응, 염증반응을 촉진시키는 중요한 사이토카인이다. 구체적으로, LPS 처리 후 녹각 영지버섯 포자오일을 0.5%(v/v), 0.25%(v/v) 또는 0.1%(v/v) 농도로 처리한 경우의 IL-6의 수준을 확인하였다. 포자오일을 처리하지 않은 군을 음성 대조군으로, LPS만을 처리한 군을 양성 대조군으로 하였다.In addition, in order to confirm the anti-inflammatory effect of deer antler reishi mushroom spore oil, ELISA was performed to confirm the level of IL-6, a pro-inflammatory cytokine, according to treatment at various concentrations of the spore oil prepared in Example 1. (enzyme-linked immunosorbent assay) was performed. IL-6 is an activating factor secreted by macrophages and is an important cytokine that promotes immune and inflammatory responses. Specifically, the level of IL-6 was confirmed when treated with deer antler reishi mushroom spore oil at a concentration of 0.5% (v/v), 0.25% (v/v), or 0.1% (v/v) after LPS treatment. The group not treated with spore oil was used as a negative control, and the group treated only with LPS was used as a positive control.
그 결과, 도 2에 나타낸 바와 같이, 녹각 영지버섯 포자오일을 처리한 경우, LPS 처리에 의해 유도된 IL-6의 수준을 유의적으로 감소시킴을 확인하였다. As a result, as shown in Figure 2, it was confirmed that treatment with deer antler reishi mushroom spore oil significantly reduced the level of IL-6 induced by LPS treatment.
상기 결과로부터, 녹각 영지버섯 포자오일은 현저히 우수한 항염 효과를 나타냄을 확인할 수 있다.From the above results, it can be confirmed that deer antler reishi mushroom spore oil exhibits a significantly excellent anti-inflammatory effect.
실험예 2. 녹각 영지버섯 포자오일의 피부 주름 개선 효과 확인Experimental Example 2. Confirmation of the effect of deer antler reishi mushroom spore oil on improving skin wrinkles
녹각 영지버섯 포자오일의 피부 주름 개선 효과를 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 처리에 따른 프로콜라겐의 생산 분석을 수행하였다. 일반적으로 피부 세포의 주름과 관련된 콜라겐은 프로콜라겐(procollagen)이라는 전구물질의 형태로 합성된다고 알려져 있으며, 프로콜라겐 펩타이드의 양을 측정함으로써, 세포 내에서의 콜라겐 합성 정도를 파악할 수 있다. 구체적으로, 녹각 영지버섯 포자오일을 0.5%(v/v), 0.25%(v/v) 또는 0.1%(v/v) 농도로 처리한 경우의 프로콜라겐의 상대적인 생산율을 확인하였다. 포자오일을 처리하지 않은 군을 음성 대조군으로, TGF-β를 처리한 군을 양성 대조군으로 하였다. In order to confirm the effect of deer antler reishi mushroom spore oil on improving skin wrinkles, procollagen production analysis was performed according to treatment at various concentrations of the spore oil prepared in Example 1. It is generally known that collagen, which is related to wrinkles in skin cells, is synthesized in the form of a precursor called procollagen. By measuring the amount of procollagen peptides, the degree of collagen synthesis within the cell can be determined. Specifically, the relative production rate of procollagen when treated with deer antler reishi mushroom spore oil at a concentration of 0.5% (v/v), 0.25% (v/v), or 0.1% (v/v) was confirmed. The group not treated with spore oil was used as a negative control, and the group treated with TGF-β was used as a positive control.
그 결과, 도 3에 나타낸 바와 같이, 녹각 영지버섯 포자오일을 처리한 경우, 프로콜라겐의 합성을 약 1.5배로 증가시킴을 확인하였다. 이는 콜라겐 합성을 유도하는 것으로 알려진 TGF-β를 처리한 양성 대조군에 상응하는 수치이다.As a result, as shown in Figure 3, it was confirmed that when treated with deer antler reishi mushroom spore oil, the synthesis of procollagen increased by about 1.5 times. This value corresponds to the positive control group treated with TGF-β, which is known to induce collagen synthesis.
또한, 녹각 영지버섯 포자오일의 피부 주름 개선 효과를 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 처리에 따른 Col1a1 mRNA의 발현 수준을 확인한 실시간 PCR을 수행하였다. 구체적으로, 녹각 영지버섯 포자오일을 0.5%(v/v), 0.25%(v/v) 또는 0.1%(v/v) 농도로 처리한 경우의 Col1a1 mRNA 발현 수준을 확인하였다. 포자오일을 처리하지 않은 군을 음성 대조군으로, TGF-β를 처리한 군을 양성 대조군으로 하였다. 상기 PCR에 사용된 Col1a1 프라이머 서열은 표 2에 기재하였다.In addition, in order to confirm the effect of deer antler reishi mushroom spore oil on improving skin wrinkles, real-time PCR was performed to check the expression level of Col1a1 mRNA according to treatment at various concentrations of the spore oil prepared in Example 1. Specifically, the expression level of Col1a1 mRNA was confirmed when treated with deer antler reishi mushroom spore oil at a concentration of 0.5% (v/v), 0.25% (v/v), or 0.1% (v/v). The group not treated with spore oil was used as a negative control, and the group treated with TGF-β was used as a positive control. The Col1a1 primer sequences used in the PCR are listed in Table 2.
그 결과, 도 4에 나타낸 바와 같이, 녹각 영지버섯 포자오일을 처리한 경우, Col1a1 mRNA 발현 수준을 약 1.5배로 증가시킴을 확인하였다. 이는 콜라겐 합성을 유도하는 것으로 알려진 TGF-β를 처리한 양성 대조군에 상응하는 수치이다. 상기 결과로부터, 녹각 영지버섯 포자오일은 현저히 우수한 피부 주름 개선 효과를 나타냄을 확인할 수 있다.As a result, as shown in Figure 4, it was confirmed that when treated with deer antler reishi mushroom spore oil, the Col1a1 mRNA expression level increased by about 1.5-fold. This value corresponds to the positive control group treated with TGF-β, which is known to induce collagen synthesis. From the above results, it can be confirmed that deer antler reishi mushroom spore oil shows a significantly excellent skin wrinkle improvement effect.
실험예 3. 녹각 영지버섯 포자오일의 피부 보습 효과 확인Experimental Example 3. Confirmation of skin moisturizing effect of deer antler reishi mushroom spore oil
녹각 영지버섯 포자오일의 피부 보습 효과를 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 처리에 따른 아쿠아포린-3(AQP-3) mRNA 발현 수준을 확인한 실시간 PCR을 수행하였다. 구체적으로, 인간 각질형성세포(keratinocyte)를 배양한 후, UVA 조사한 그룹과 조사하지 않은 그룹으로 나누어 녹각영지 포자오일을 각각 0.5%(v/v), 0.25%(v/v) 농도로 처리하고 mRNA를 수득하여 AQP-3 발현량을 비교 분석하였다. 포자오일을 처리하지 않은 군을 음성 대조군으로, TGF-β를 처리한 군을 양성 대조군으로 하였다. 상기 PCR에 사용된 AQP-3 프라이머 서열은 하기 표 3에 기재하였다.In order to confirm the skin moisturizing effect of deer antler reishi mushroom spore oil, real-time PCR was performed to confirm the expression level of aquaporin-3 (AQP-3) mRNA according to treatment at various concentrations of the spore oil prepared in Example 1. Specifically, after culturing human keratinocytes, they were divided into UVA-irradiated and non-UVA-irradiated groups and treated with Antler Reishi spore oil at concentrations of 0.5% (v/v) and 0.25% (v/v), respectively. mRNA was obtained and the expression level of AQP-3 was compared and analyzed. The group not treated with spore oil was used as a negative control, and the group treated with TGF-β was used as a positive control. The AQP-3 primer sequences used in the PCR are listed in Table 3 below.
그 결과, 도 5에 나타낸 바와 같이, 자외선을 조사하지 않은 경우에는 녹각 영지버섯 포자오일을 처리한 군에서 AQP-3 mRNA 발현 수준을 약 25% 증가시킴을 확인하였다. 자외선을 조사한 경우에도, 녹각 영지버섯 포자오일을 처리한 군에서 AQP-3 mRNA 발현 수준을 약 30% 증가시킴을 확인하였다.상기 결과로부터, 녹각 영지버섯 포자오일은 현저히 우수한 피부 보습 효과를 나타내는 것이고, 특히, 자외선 조사에 의해 손실된 피부 수분을 정상 피부 수준으로 회복시킬 수 있음을 확인할 수 있다.As a result, as shown in Figure 5, it was confirmed that in the case where ultraviolet rays were not irradiated, the AQP-3 mRNA expression level was increased by about 25% in the group treated with deer antler reishi mushroom spore oil. Even when irradiated with ultraviolet rays, it was confirmed that the AQP-3 mRNA expression level increased by about 30% in the group treated with deer antler reishi mushroom spore oil. From the above results, it can be seen that deer antler reishi mushroom spore oil has a significantly excellent skin moisturizing effect. , In particular, it can be confirmed that skin moisture lost by ultraviolet irradiation can be restored to normal skin level.
이상의 결과로부터, 본 발명의 화장료 조성물은 녹각 영지버섯 포자오일을 유효성분으로 포함함으로써, 현저히 개선된 항염, 피부 주름 개선, 피부 보습력을 나타냄을 확인할 수 있다.From the above results, it can be confirmed that the cosmetic composition of the present invention exhibits significantly improved anti-inflammatory, skin wrinkle improvement, and skin moisturizing properties by containing deer antler reishi mushroom spore oil as an active ingredient.
실험예 4.Experimental Example 4. 녹각 영지버섯 포자오일의 세포 독성 시험Cytotoxicity test of deer antler reishi mushroom spore oil
녹각 영지버섯 포자오일의 세포 독성을 확인하기 위해, 상기 실시예 1에서 제조된 포자오일의 다양한 농도에서 cell viability assay를 수행하였다. 구체적으로, 녹각 영지버섯 포자오일을 2%(v/v), 1%(v/v), 0.5%(v/v), 0.25%(v/v) 또는 0.1%(v/v) 농도로 처리한 경우의 세포 생존률을 확인하였다. 포자오일을 처리하지 않은 군(MO: media only)을 음성 대조군으로 하였다.To confirm the cytotoxicity of the deer antler reishi mushroom spore oil, a cell viability assay was performed at various concentrations of the spore oil prepared in Example 1 above. Specifically, deer antler reishi mushroom spore oil was used at a concentration of 2% (v/v), 1% (v/v), 0.5% (v/v), 0.25% (v/v), or 0.1% (v/v). Cell survival rate when treated was confirmed. The group not treated with spore oil (MO: media only) was used as a negative control.
도 6은 녹각 영지버섯 포자오일의 세포 독성 시험 결과이다.Figure 6 shows the cytotoxicity test results of deer antler reishi mushroom spore oil.
도 6에 나타낸 바와 같이, 녹각 영지버섯 포자오일을 1%(v/v) 미만으로 사용할 경우 세포 독성이 없어 안전한 것을 알 수 있었다.As shown in Figure 6, when the deer antler reishi mushroom spore oil was used in an amount of less than 1% (v/v), it was found to be safe as there was no cytotoxicity.
실험예 5. 녹각 영지버섯 포자오일 나노리포좀의 크기 및 제형 안정성 확인Experimental Example 5. Confirmation of size and formulation stability of deer antler reishi mushroom spore oil nanoliposomes
실시예 2에서 제조한 녹각 영지버섯 포자오일 나노리포좀의 크기 및 제형 안정성을 확인하기 위한 실험을 하였다. 구체적으로, 나노입도 분석기(제타사이저 나노(모델명: NANO ZS), 말번코리아, 영국)를 이용하여 나노리포좀의 크기를 측정하였다.An experiment was conducted to confirm the size and formulation stability of the deer antler reishi mushroom spore oil nanoliposomes prepared in Example 2. Specifically, the size of nanoliposomes was measured using a nanoparticle size analyzer (Zetasizer Nano (model name: NANO ZS), Malvern Korea, UK).
도 7은 녹각 영지버섯 포자오일 나노리포좀의 크기 분포를 나타낸 그래프이다. 빨간색 라인: 초기 측정 결과; 녹색 라인: -10℃에서 5개월간 보관 후 측정 결과.Figure 7 is a graph showing the size distribution of deer antler reishi mushroom spore oil nanoliposomes. Red line: initial measurement result; Green line: Measurement results after storage at -10℃ for 5 months.
도 7에 나타낸 바와 같이, 실시예 2에서 제조한 녹각 영지버섯 포자오일 나노리포좀은 평균 입자 크기가 98 nm였다. 또한, 상기 나노리포좀은 -10℃에서 5개월간 보관하여도 입자 크기의 변화가 없어 매우 우수한 제형 안정성을 가진다는 것을 확인하였다.As shown in Figure 7, the antler reishi mushroom spore oil nanoliposomes prepared in Example 2 had an average particle size of 98 nm. In addition, it was confirmed that the nanoliposomes had excellent formulation stability as there was no change in particle size even when stored at -10°C for 5 months.
<110> Intercare Chodang university WEE, hyoun <120> Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same <130> PN135716 <150> KR 10-2019-0122502 <151> 2019-10-02 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col1a1_forward <400> 1 agggccaaga cgaagacatc 20 <210> 2 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Col1a1_reverse <400> 2 agatcacgtc atcgcacaac a 21 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> AQP3_forward <400> 3 agacagcccc ttcaggattt 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> AQP3_reverse <400> 4 tcccttgccc tgaatatctg 20 <110> Intercare Chodang University WEE, hyoun <120> Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same <130> PN135716 <150> KR 10-2019-0122502 <151> 2019-10-02 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Col1a1_forward <400> 1 agggccaaga cgaagacatc 20 <210> 2 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Col1a1_reverse <400> 2 agatcacgtc atcgcacaac a 21 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> AQP3_forward <400> 3 agacagcccc ttcaggattt 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> AQP3_reverse <400> 4 tcccttgccc tgaatatctg 20
Claims (10)
조성물 총 중량에 대해 상기 녹각 영지버섯 포자오일을 0.1%(v/v) 내지 0.5%(v/v)로 포함하고,
상기 녹각 영지버섯 포자오일은, 에탄올, 메탄올, 물, 에틸아세테이트, 헥산, 및 에틸에테르 중에서 선택되는 1종 이상과 녹각 영지버섯 포자를 혼합한 혼합물에 초임계 유체를 공급하여 30 내지 50℃ 및 250 내지 400 기압의 조건에서 10분 내지 120분 동안 초임계 추출하여 제조된 것인, 피부 상태 개선용 화장료 조성물.A cosmetic composition for improving skin condition containing deer antler reishi mushroom spore oil or nanoliposomes containing it,
The composition contains 0.1% (v/v) to 0.5% (v/v) of the deer antler reishi mushroom spore oil based on the total weight of the composition,
The deer antler reishi mushroom spore oil is obtained by supplying a supercritical fluid to a mixture of deer antler reishi mushroom spores and at least one selected from ethanol, methanol, water, ethyl acetate, hexane, and ethyl ether at 30 to 50° C. and 250° C. A cosmetic composition for improving skin condition, prepared by supercritical extraction for 10 to 120 minutes under conditions of 400 to 400 atmospheres.
조성물 총 중량에 대해 상기 녹각 영지버섯 포자오일을 0.1%(v/v) 내지 0.5%(v/v)로 포함하고,
상기 녹각 영지버섯 포자오일은, 에탄올, 메탄올, 물, 에틸아세테이트, 헥산, 및 에틸에테르 중에서 선택되는 1종 이상과 녹각 영지버섯 포자를 혼합한 혼합물에 초임계 유체를 공급하여 30 내지 50℃ 및 250 내지 400 기압의 조건에서 10분 내지 120분 동안 초임계 추출하여 제조된 것인, 피부 상태 개선용 식품 조성물.A food composition for improving skin condition containing deer antler reishi mushroom spore oil or nanoliposomes containing it,
The composition contains 0.1% (v/v) to 0.5% (v/v) of the deer antler reishi mushroom spore oil based on the total weight of the composition,
The deer antler reishi mushroom spore oil is obtained by supplying a supercritical fluid to a mixture of deer antler reishi mushroom spores and at least one selected from ethanol, methanol, water, ethyl acetate, hexane, and ethyl ether at 30 to 50° C. and 250° C. A food composition for improving skin condition, prepared by supercritical extraction for 10 to 120 minutes under conditions of 400 to 400 atmospheres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190122502 | 2019-10-02 | ||
KR1020190122502 | 2019-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210039959A KR20210039959A (en) | 2021-04-12 |
KR102595837B1 true KR102595837B1 (en) | 2023-10-30 |
Family
ID=75439851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200126392A KR102595837B1 (en) | 2019-10-02 | 2020-09-28 | Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102595837B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736731A (en) * | 2022-04-27 | 2022-07-12 | 山东芝人堂药业有限公司 | Supercritical CO2 process for extracting ganoderma lucidum spore oil |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101744759A (en) | 2008-12-04 | 2010-06-23 | 南京仑狄贸易实业有限公司 | Application of ganoderma lucidum spore oil encapsulated by human embryo and brain phospholipid liposome in the cosmetic field |
KR101213270B1 (en) * | 2006-11-09 | 2012-12-17 | 가부시키가이샤 미죠타 | Method and apparatus for extracting useful substance from deer horn shaped ganoderma lucidum |
CN105853286A (en) * | 2016-04-29 | 2016-08-17 | 山东复大生物科技有限公司 | Skin care product containing ganoderma lucidum spore oil and preparation method for ganoderma lucidum spores oil of skin care product |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02184613A (en) * | 1989-01-09 | 1990-07-19 | Nonogawa Shoji:Kk | Skin cosmetic |
KR100530880B1 (en) * | 2003-12-05 | 2005-11-23 | 한국콜마 주식회사 | The cosmetic products of phospholipid liposome with nano-particle size and its manufacturing method |
-
2020
- 2020-09-28 KR KR1020200126392A patent/KR102595837B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101213270B1 (en) * | 2006-11-09 | 2012-12-17 | 가부시키가이샤 미죠타 | Method and apparatus for extracting useful substance from deer horn shaped ganoderma lucidum |
CN101744759A (en) | 2008-12-04 | 2010-06-23 | 南京仑狄贸易实业有限公司 | Application of ganoderma lucidum spore oil encapsulated by human embryo and brain phospholipid liposome in the cosmetic field |
CN105853286A (en) * | 2016-04-29 | 2016-08-17 | 山东复大生物科技有限公司 | Skin care product containing ganoderma lucidum spore oil and preparation method for ganoderma lucidum spores oil of skin care product |
Also Published As
Publication number | Publication date |
---|---|
KR20210039959A (en) | 2021-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102598793B1 (en) | Composition comprising ginseng derived exosome like vesicles for skin whitening | |
CN111053716B (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
JP2007186457A (en) | Tryptase activity inhibitor and its utilization | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
ES2923931T3 (en) | Fermented product and production method thereof | |
KR102117218B1 (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
KR102144568B1 (en) | Composition for skin conditioning comprising Morus alba L. extract | |
KR102595837B1 (en) | Cosmetic composition comprising spore oil extracted from antler-shaped Ganoderma lucidum and the method for preparing the same | |
US20200078290A1 (en) | Cosmetic Composition Comprising Extract Of Medicinal Herbs As Active Ingredient | |
KR20190063549A (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
KR102077708B1 (en) | Composition for skin-whitening and anti-winkle comprising extract of Poria cocos, Coix lachrymajobi and Stachys sieboldii fermented using Hericium erinaceum mycelium as effective component | |
KR20200083293A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
KR102067283B1 (en) | A skin-care agent or cosmetics containig Morchella esculenta fruit body extract or Morchella esculenta mycelium extract | |
KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
JP4247091B2 (en) | Skin anti-aging agent | |
EP2601959B1 (en) | Elastase inhibitor | |
KR20160008942A (en) | A composition comprising fermented Myrothamnus flabellifolius extract and the use thereof | |
KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR101419587B1 (en) | Composition for Promoting Regeneration of Skin Comprising Ginseng Oil as Active Ingredient | |
TW202102239A (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
KR101951816B1 (en) | Cosmetic composition containing vaccinium vitis-idaea fruit extract fermented by aureobasidium pullulans | |
KR102290291B1 (en) | Composition for improving moisturizing skin containing fermented blueberry and black rice extracts | |
KR102468186B1 (en) | Composition for Skin-lightening Using an Extract of Lotus corniculatus var. japonica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |